Optinose, INC Form 4 insider transactions

Following the merger of OptiNose with Paratek Pharmaceuticals, Chief Legal Officer Michael F. Marino III reports the disposal of common stock and stock options.

Following the merger of OptiNose with Paratek Pharmaceuticals, CFO Terry Kohler reports the disposal of common stock and stock options as part of the merger agreement.

Director John Fletcher's stock options in OptiNose were canceled or converted to contingent value rights (CVRs) following the merger with Paratek Pharmaceuticals on May 21, 2025.

Sandra L. Helton, a director of OptiNose, Inc., reports changes in beneficial ownership of securities following the merger with Paratek Pharmaceuticals, including the conversion of stock options into cash and contingent value rights.

Following the merger of OptiNose with Paratek Pharmaceuticals, a director's stock options were converted into cash and contingent value rights (CVRs) based on the merger agreement.

Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., reports the disposal of common stock and stock options due to the merger with Paratek Pharmaceuticals, Inc.

Director Eric Bednarski reports changes in stock option holdings due to the merger between OptiNose and Paratek Pharmaceuticals, including cash consideration and contingent value rights.

Director Tomas J. Heyman reports cancellation of stock options in OptiNose, Inc. following the merger with Paratek Pharmaceuticals, where each share was converted into cash and contingent value rights.

Ramy Mahmoud, CEO of OptiNose, reports the disposal of common stock and stock options due to the merger with Paratek Pharmaceuticals, where OptiNose became a wholly-owned subsidiary of Paratek.

Director Kyle Dempsey reports changes in stock option holdings due to the merger between OptiNose and Paratek Pharmaceuticals, including cash consideration and contingent value rights.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold 246 shares of common stock on March 18, 2025, to cover tax withholding obligations related to vesting restricted share units.

OptiNose CEO Ramy Mahmoud sold 368 shares of common stock on March 18, 2025, to cover tax withholding obligations related to the vesting of restricted share units.

Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., sold 1,223 shares of common stock on March 4, 2025, to cover tax withholding obligations related to vesting restricted share units.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold 2,145 shares of common stock on March 4, 2025, to cover tax withholding obligations related to vesting restricted share units.

OptiNose CEO Ramy Mahmoud sold 6,376 shares of common stock on March 4, 2025, to cover tax withholding obligations related to the vesting of restricted share units.

CEO Ramy Mahmoud reports acquisition of restricted stock units and stock options in OptiNose, Inc.

Chief Financial Officer of OptiNose, Terry Kohler, reports the acquisition of restricted stock units and stock options, according to a Form 4 filing with the SEC.

Chief Legal Officer Michael F. Marino III reports the acquisition of restricted stock units and stock options in OptiNose, Inc.

Chief Commercial Officer Paul Spence Jr. of OptiNose, Inc. reports the grant of restricted stock units and stock options.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold 3,050 shares of common stock on December 17, 2024, to cover tax withholding obligations related to the vesting of restricted share units.

OptiNose CEO Ramy Mahmoud sold 4,614 shares of common stock on December 17, 2024, to cover tax withholding obligations related to the vesting of restricted share units.

OptiNose CFO Terry Kohler was granted 150,000 restricted stock units and options to purchase 675,000 shares of common stock on October 7, 2024.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold shares to cover tax withholding obligations related to vesting restricted share units.

OptiNose CEO Ramy Mahmoud sold 4,881 shares of common stock on September 17, 2024, to cover tax withholding obligations related to the vesting of restricted share units.

Anthony J. Krick, Chief Accounting Officer of OptiNose, Inc., sold shares to cover tax withholding obligations related to the vesting of restricted share units.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold 49,408 shares of common stock on July 17, 2024, to cover tax withholding obligations related to the vesting of restricted share units.

OptiNose CEO Ramy A. Mahmoud sold 111,426 shares of common stock on July 17, 2024, to cover tax withholding obligations related to the vesting of restricted share units.

Anthony J. Krick, Chief Accounting Officer of OptiNose, Inc., sold 624 shares of common stock on June 18, 2024, to cover tax withholding obligations related to vesting restricted share units.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold 2,946 shares of common stock on June 18, 2024, to cover tax withholding obligations related to vesting restricted share units.

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., sold shares to cover tax obligations following the vesting of performance-based restricted stock units.